UoB publishes the results from a study commissioned to Neuregenix under the 2016 MRC CiC award to Ann Logan where they showed efficacy of an eye drop formulation of anti-VEGF drugs to topically to treat AMD
Neuregenix successfully completes a long series of studies for AbbVie evaluating the efficacy of novel therapeutic monoclonal antibodies for neurological conditions.
Tikomed signs new collaboration agreements with University of Birmingham and Neuregenix to carry out a pipeline of pre-clinical and clinical trials of ILB for ocular and neurodegenerative conditions.
Neuregenix Brochure Publications
A strong partnership with the College of Medicine and Dentistry – March 19, 2018 UoB publishes the results from a study commissioned to Neuregenix under the 2016 MRC CiC award to Ann Logan where they showed efficacy of an eye drop formulation of anti-VEGF drugs to topically to treat AMD – December 04, 2017 Neuregenix successfully completes a long series of studies for AbbVie evaluating the efficacy of novel therapeutic monoclonal antibodies for neurological conditions. – December 01, 2017 Tikomed signs new collaboration agreements with University of Birmingham and Neuregenix to carry out a pipeline of pre-clinical and clinical trials of ILB for ocular and neurodegenerative conditions. – November 01, 2017 Neuregenix joins the industrial advisory board underpinning the new science for health training program, 2015 – May 06, 2015
website by whitespace